Credit: Shutterstock photoBy Todd Shriber via Iris.xyz While the biotechnology space is one of the most innovative corners of the investment landscape, some potentially lucrative drugs and therapies are under-represented in traditional biotech investment vehicles. It is common for large-cap biotech investments, including funds, to feature exposure to companies working on treatments for well-known diseases, such as cancer, [...] Read more on ETFtrends.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This article was provided by our partner Tom Lydon of etftrends.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
